Hong Kong exchange seizes the moment: a Perspective

Growing momentum at the Hong Kong stock exchange and chaotic policies from the White House may upend the longstanding IPO calculus for Asia’s biotechs. 

As recently as early March, bankers, investors and CFOs were still telling me at BioCentury’s East-West Summit in Singapore that NASDAQ was the only market Asia’s biotechs should bother considering when going public...